Paper Details

  1. Home
  2. Paper Details

Role of dopamine receptor agonists in the treatment of early Parkinson's disease.

Author: BonuccelliUbaldo, Del DottoPaolo, RascolOlivier

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Dopamine receptor agonists have become increasingly important in treating Parkinson's disease (PD). They are used both as adjunctive therapy with L-dopa and as initial monotherapy for early PD. While dopamine receptor agonists may delay motor complications associated with long-term L-dopa therapy, they have a smaller effect on motor symptoms and can cause side effects such as somnolence, hallucinations, and leg edema. Ergot derivatives are not recommended as first-line treatment due to the risk of fibrotic reactions. In younger patients, initial treatment with dopamine receptor agonists is recommended.
Paper Details　
Original Abstract of the Article :
In the last two decades, the usefulness of dopamine receptor agonists in the symptomatic treatment of Parkinson' disease (PD) has been demonstrated in many randomized controlled clinical trials. The initial role of such compounds as an adjunctive therapy to L-dopa to improve motor fluctuations has n...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S1353-8020(09)70835-1

データ提供：米国国立医学図書館（NLM）

Dopamine Receptor Agonists: A New Frontier in Parkinson's Disease Treatment

Parkinson's disease (PD), a progressive neurological disorder, can significantly impact the quality of life of those affected. This review examines the role of dopamine receptor agonists in the treatment of early PD, highlighting their potential benefits and risks.

Dopamine Receptor Agonists: Delaying Motor Complications

The authors discuss the rationale for using dopamine receptor agonists as initial monotherapy in early PD. These agents can help to delay or reduce the incidence of motor complications associated with long-term L-dopa therapy. The study highlights the results of clinical trials that have shown dopamine receptor agonists, such as cabergoline, pergolide, pramipexole, and ropinirole, to be effective in reducing the risk of motor fluctuations and dyskinesias.

Navigating the Complexities of PD Treatment

The review also discusses the potential side effects of dopamine receptor agonists, such as somnolence, hallucinations, and leg edema. The authors emphasize the importance of careful patient monitoring and the need for individualized treatment plans. Just as a camel carefully chooses its path through the desert, clinicians must consider each patient's unique needs and circumstances when managing PD.

Dr.Camel's Conclusion

This review provides a comprehensive overview of the role of dopamine receptor agonists in the treatment of early PD. The findings suggest that these agents can be effective in delaying motor complications and improving quality of life. However, it's crucial to be aware of potential side effects and to monitor patients carefully.

Date :
  1. Date Completed 2010-09-30
  2. Date Revised 2010-02-03
Further Info :

Pubmed ID

20123557

DOI: Digital Object Identifier

10.1016/S1353-8020(09)70835-1

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.